Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Establishing estrogen-responsive mouse mammary organoids from single Lgr5+ cells.

Zhang L, Adileh M, Martin ML, Klingler S, White J, Ma X, Howe LR, Brown AM, Kolesnick R.

Cell Signal. 2017 Jan;29:41-51. doi: 10.1016/j.cellsig.2016.08.001. Epub 2016 Aug 7.

2.

Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer.

Iyengar NM, Zhou XK, Gucalp A, Morris PG, Howe LR, Giri DD, Morrow M, Wang H, Pollak M, Jones LW, Hudis CA, Dannenberg AJ.

Clin Cancer Res. 2016 May 1;22(9):2283-9. doi: 10.1158/1078-0432.CCR-15-2239. Epub 2015 Dec 28.

3.

Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer.

Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ.

Clin Cancer Res. 2013 Nov 15;19(22):6074-83. doi: 10.1158/1078-0432.CCR-12-2603. Epub 2013 Aug 19.

4.

Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary tumor growth and angiogenesis.

Howe LR, Subbaramaiah K, Kent CV, Zhou XK, Chang SH, Hla T, Jakobsson PJ, Hudis CA, Dannenberg AJ.

Prostaglandins Other Lipid Mediat. 2013 Oct;106:99-105. doi: 10.1016/j.prostaglandins.2013.04.002. Epub 2013 Apr 25.

5.

Identification of PADI2 as a potential breast cancer biomarker and therapeutic target.

McElwee JL, Mohanan S, Griffith OL, Breuer HC, Anguish LJ, Cherrington BD, Palmer AM, Howe LR, Subramanian V, Causey CP, Thompson PR, Gray JW, Coonrod SA.

BMC Cancer. 2012 Oct 30;12:500. doi: 10.1186/1471-2407-12-500.

6.

Cyclooxygenase-2-derived prostacyclin regulates arterial thrombus formation by suppressing tissue factor in a sirtuin-1-dependent-manner.

Barbieri SS, Amadio P, Gianellini S, Tarantino E, Zacchi E, Veglia F, Howe LR, Weksler BB, Mussoni L, Tremoli E.

Circulation. 2012 Sep 11;126(11):1373-84. doi: 10.1161/CIRCULATIONAHA.112.097295. Epub 2012 Aug 3.

PMID:
22865892
7.

Pioglitazone, a PPARγ agonist, suppresses CYP19 transcription: evidence for involvement of 15-hydroxyprostaglandin dehydrogenase and BRCA1.

Subbaramaiah K, Howe LR, Zhou XK, Yang P, Hudis CA, Kopelovich L, Dannenberg AJ.

Cancer Prev Res (Phila). 2012 Oct;5(10):1183-94. doi: 10.1158/1940-6207.CAPR-12-0201. Epub 2012 Jul 10.

8.

Activation status of Wnt/ß-catenin signaling in normal and neoplastic breast tissues: relationship to HER2/neu expression in human and mouse.

Khalil S, Tan GA, Giri DD, Zhou XK, Howe LR.

PLoS One. 2012;7(3):e33421. doi: 10.1371/journal.pone.0033421. Epub 2012 Mar 23.

9.

Targeting the HER/EGFR/ErbB family to prevent breast cancer.

Howe LR, Brown PH.

Cancer Prev Res (Phila). 2011 Aug;4(8):1149-57. doi: 10.1158/1940-6207.CAPR-11-0334. Review.

10.

Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland.

Subbaramaiah K, Howe LR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK, Zhou XK, Blaho VA, Hla T, Yang P, Kopelovich L, Hudis CA, Dannenberg AJ.

Cancer Prev Res (Phila). 2011 Mar;4(3):329-46. doi: 10.1158/1940-6207.CAPR-10-0381.

11.

Pea3 transcription factors and wnt1-induced mouse mammary neoplasia.

Baker R, Kent CV, Silbermann RA, Hassell JA, Young LJ, Howe LR.

PLoS One. 2010 Jan 22;5(1):e8854. doi: 10.1371/journal.pone.0008854.

12.

Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.

Brown PH, Subbaramaiah K, Salmon AP, Baker R, Newman RA, Yang P, Zhou XK, Bissonnette RP, Dannenberg AJ, Howe LR.

Cancer Prev Res (Phila). 2008 Aug;1(3):208-14. doi: 10.1158/1940-6207.CAPR-08-0021.

13.

Meeting report: Sixth Annual AACR International Conference on Frontiers in Cancer Prevention Research.

Girnun GD, Howe LR, Manne S, Mao JT, Reid ME, Szabo E.

Cancer Prev Res (Phila). 2008 Jul;1(2):146-9. doi: 10.1158/1940-6207.CAPR-08-0023.

14.

Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs.

Howe LR, Lippman SM.

J Natl Cancer Inst. 2008 Oct 15;100(20):1420-3. doi: 10.1093/jnci/djn347. Epub 2008 Oct 7. No abstract available.

15.

Rexinoids and breast cancer prevention.

Howe LR.

Clin Cancer Res. 2007 Oct 15;13(20):5983-7. Review. No abstract available.

16.
17.

HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism.

Subbaramaiah K, Howe LR, Port ER, Brogi E, Fishman J, Liu CH, Hla T, Hudis C, Dannenberg AJ.

Cancer Res. 2006 May 15;66(10):5504-11.

18.

HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice.

Howe LR, Chang SH, Tolle KC, Dillon R, Young LJ, Cardiff RD, Newman RA, Yang P, Thaler HT, Muller WJ, Hudis C, Brown AM, Hla T, Subbaramaiah K, Dannenberg AJ.

Cancer Res. 2005 Nov 1;65(21):10113-9.

19.

Germline mutations of AXIN2 are not associated with nonsyndromic colorectal cancer.

Peterlongo P, Howe LR, Radice P, Sala P, Hong YJ, Hong SI, Mitra N, Offit K, Ellis NA.

Hum Mutat. 2005 May;25(5):498-500. No abstract available.

PMID:
15841489
20.

Truncated mutants of the putative Wnt receptor LRP6/Arrow can stabilize beta-catenin independently of Frizzled proteins.

Brennan K, Gonzalez-Sancho JM, Castelo-Soccio LA, Howe LR, Brown AM.

Oncogene. 2004 Jun 17;23(28):4873-84.

21.

Extracellular matrix-induced cyclooxygenase-2 regulates macrophage proteinase expression.

Khan KM, Howe LR, Falcone DJ.

J Biol Chem. 2004 May 21;279(21):22039-46. Epub 2004 Mar 15.

22.

Wnt signaling and breast cancer.

Howe LR, Brown AM.

Cancer Biol Ther. 2004 Jan;3(1):36-41. Epub 2004 Jan 14. Review.

PMID:
14739782
23.

COX-2 inhibitors for the prevention of breast cancer.

Howe LR, Dannenberg AJ.

J Mammary Gland Biol Neoplasia. 2003 Jan;8(1):31-43. Review.

PMID:
14587862
24.

The role of COX-2 in breast and cervical cancer.

Dannenberg AJ, Howe LR.

Prog Exp Tumor Res. 2003;37:90-106. Review. No abstract available.

PMID:
12795050
25.

Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation.

Howe LR, Watanabe O, Leonard J, Brown AM.

Cancer Res. 2003 Apr 15;63(8):1906-13.

26.

Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.

Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AM, Dannenberg AJ.

Cancer Res. 2002 Oct 1;62(19):5405-7.

27.

A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer.

Howe LR, Dannenberg AJ.

Semin Oncol. 2002 Jun;29(3 Suppl 11):111-9. Review.

PMID:
12138405
28.

Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer.

Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, Subbaramaiah K.

Lancet Oncol. 2001 Sep;2(9):544-51. Review.

PMID:
11905709
29.

Elevated expression of cyclooxygenase-2 contributes to immune dysfunction in a murine model of trauma.

Mackrell PJ, Daly JM, Mestre JR, Stapleton PP, Howe LR, Subbaramaiah K, Dannenberg AJ.

Surgery. 2001 Nov;130(5):826-33.

PMID:
11685192
30.

Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.

Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ.

Endocr Relat Cancer. 2001 Jun;8(2):97-114. Review.

PMID:
11397667
31.

PEA3 is up-regulated in response to Wnt1 and activates the expression of cyclooxygenase-2.

Howe LR, Crawford HC, Subbaramaiah K, Hassell JA, Dannenberg AJ, Brown AM.

J Biol Chem. 2001 Jun 8;276(23):20108-15. Epub 2001 Mar 26.

32.

Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cells.

Howe LR, Subbaramaiah K, Chung WJ, Dannenberg AJ, Brown AM.

Cancer Res. 1999 Apr 1;59(7):1572-7.

33.

Multiple kinases mediate T-cell-receptor signaling.

Howe LR, Weiss A.

Trends Biochem Sci. 1995 Feb;20(2):59-64. Review.

PMID:
7701563
35.

A dominant-negative mutant of raf blocks mitogen-activated protein kinase activation by growth factors and oncogenic p21ras.

Schaap D, van der Wal J, Howe LR, Marshall CJ, van Blitterswijk WJ.

J Biol Chem. 1993 Sep 25;268(27):20232-6.

36.

Identification of amino acids in p21ras involved in exchange factor interaction.

Howe LR, Marshall CJ.

Oncogene. 1993 Sep;8(9):2583-90.

PMID:
8361768
37.

Activation of the MAP kinase pathway by the protein kinase raf.

Howe LR, Leevers SJ, Gómez N, Nakielny S, Cohen P, Marshall CJ.

Cell. 1992 Oct 16;71(2):335-42.

PMID:
1330321
38.

Extraction and recovery of inositol phosphates from tissues.

Wreggett KA, Howe LR, Moore JP, Irvine RF.

Biochem J. 1987 Aug 1;245(3):933-4. No abstract available.

39.

Supplemental Content

Support Center